I thought that an agreement would come quicker, ans, also, I underestimated the process for reimbursment.
Now we are there. My unarticulated opponents is somewhat predictable: There will be no sales? :-)
I am not sure, but maybe there is a delay for the money to reach Epicept from Meda by a quarter? We have had reimbursment deals in italy and Sweden. We also have had an increase in price.
Meda needs a stock after the reimbursmentdeals. Delivery under Q2. As we are waiting for the French reimbursment deal.
On Swedish boards Revlemids sales have been an example for a possible outcome for Ceplene: It took 2 years of no meaningful sales, but, after the reimbursment deal in Sweden, sales skyrocket from SEK 1 to 35 millions in one year.